🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

🧪

Trial Match

Clinical trials test new treatments — sometimes the newest options available for a disease. Find trials that are recruiting now, near you. Open one to see its eligibility rules as simple questions to go through with your doctor.

Know your stage or your test results (such as EGFR, HER2 or BRCA)? Match trials to your own profile - nothing you type is saved.

🎯 Match trials to me

7 recruiting trials

for Psychosis Associated With Alzheimer's Disease

A Study to Evaluate Safety and Efficacy of KarXT + KarX-EC as a Treatment for Psychosis Associated With Alzheimer's Disease (ADEPT-5) NCT06947941Phase 322 sites📍 Gilbert📍 Chino📍 Naples Bristol-Myers Squibb · Tests: KarXT, KarX-EC, KarXT + KarX-EC Arm Matching Placebo A Study to Assess the Efficacy and Safety of ITI-1284 in the Treatment of Psychosis Associated With Alzheimer's Disease NCT06540833Phase 269 sites📍 Anaheim📍 Los Alamitos📍 Newport Beach Intra-Cellular Therapies, Inc. · Tests: ITI-1284, Placebo A Study to Evaluate KarXT as a Treatment for Psychosis Associated With Alzheimer's Disease (ADEPT-4) NCT06585787Phase 3296 sites📍 Chandler📍 Gilbert📍 Phoenix Karuna Therapeutics, Inc., a Bristol Myers Squibb company · Tests: KarXT, Placebo A Study to Assess Efficacy and Safety of KarXT for the Treatment of Psychosis Associated With Alzheimer's Disease (ADEPT-1) NCT05511363Phase 3129 sites📍 Homewood📍 Phoenix📍 Encino Karuna Therapeutics, Inc., a Bristol Myers Squibb company · Tests: KarXT, Placebo A Study to Assess the Efficacy and Safety of ML-007C-MA for the Treatment of Alzheimer's Disease Psychosis NCT06887192Phase 262 sites📍 Phoenix📍 Scottsdale📍 Tucson MapLight Therapeutics · Tests: ML-007C-MA, Placebo A Study to Assess Efficacy and Safety of KarXT for the Treatment of Psychosis Associated With Alzheimer's Disease (ADEPT-2) NCT06126224Phase 3157 sites📍 Chandler📍 Phoenix📍 Anaheim Karuna Therapeutics, Inc., a Bristol Myers Squibb company · Tests: KarXT, Placebo Open-Label Extension Study to Assess the Long-Term Safety and Tolerability of KarXT in Subjects With Psychosis Associated With Alzheimer's Disease (ADEPT-3) NCT05980949Phase 3432 sites📍 Homewood📍 Chandler📍 Chandler Karuna Therapeutics, Inc., a Bristol Myers Squibb company · Tests: KarXT
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy